baber/WOPTO huggingface dataset:
Patent NZ-550548-A (NZ)
Title: Tricyclic aromatic and bis-phenyl sulfinyl derivatives
Inventor: BACON EDWARD R
IPC: C07C323/49
Filed: 2005-04-13
Abstract: Disclosed are tricyclic and bis-phenyl sulfonyl compounds of formula (IV) wherein the substituents are as defined in the specification used for the treatment of diseases such as excessive sleepiness, Parkinson's disease, Alzheimer's disease and attention deficit disorder.
Patent NZ-560992-A (NZ)
Title: The use of carbazole derivatives for the treatment or prophylaxis of diseases or conditions caused by ischaemic damage to tissues of peripheral organs
Inventor: WULFERT ERNST
IPC: A61K31/403
Filed: 2006-02-02
Abstract: Disclosed is the use of carbazole derivatives of general formula (I), in which: X represents >CR1R2 or, when R6 does not represent a hydrogen atom, X can also represent >SO2; Y is >CR1R2; Z is >C=O, >CH2 or a direct bond; R1 is hydrogen atom and R2 is hydrogen, a carboxy group or a hydroxy group; or R1 and R2 together represent an oxo group, an ethylenedioxy group or a hydroxyimino group; R3 is hydrogen or alkyl; R4 represents two hydrogen atoms, or an oxo or hydroxyimino group; R5 is hydrogen, alkyl or halogen; R6 is hydrogen, alkoxy, or a carboxy group; R7 and R8 are independently represented by hydrogen, alkyl or halogen; and pharmaceutically acceptable salts and esters thereof for the manufacture of a medicament for the treatment or prophylaxis of diseases or conditions caused by ischaemic damage to tissues of peripheral organs. Of particular importance are the compounds 7,8-dimethyl-2,3,4,9-tetrahydro-1H-carbazol-3-ol, 5,8-dimethyl-2,3,4,9-tetrahydro-1H-carbazol-3-ol, 8-methoxy-1,3,4,5-tetrahydrothiopyrano[4,3-b]indole 2,2-dioxide and 5,8-dimethyl-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid,
Patent NZ-563541-A (NZ)
Title: Cooling room
Inventor: WEETH FREDERIC R
IPC: E04H7/22
Filed: 2006-05-01
Abstract: A cooling room 200 includes first and second common plenum walls 222, 224 located between the first side wall 36 and the second side wall 38 of a box like housing, and located respectively proximate the first and second side walls to create first and second plenums 218, 220 between the first and second common plenum walls and the first and second side walls respectively, and a treatment zone 216 between the first and second common plenum walls. A flow barrier includes a flat planar member 204 retractably connected to the ceiling 210 of the housing and being retractably extendable from the ceiling into the treatment zone to reduce the overall height of the treatment zone. A row of pallets 222, 224 can be accommodated within the treatment zone. The first and second plenum each has an opening to allow the passage of conditioning air to pass through the plenum and the first and second common plenum walls are provided with a plurality of openings to allow conditioning air to pass between the plenum and the treatment zone. A ventilator communicates with the second opening of the second plenum to provide circulation to the conditioning air.
Patent NZ-568585-A (NZ)
Title: Mortar composition, method for the production thereof and its use
Inventor: LAUDET ALAIN
IPC: C04B24/08
Filed: 2006-11-02
Abstract: Disclosed is a mortar composition in the form of dry powder, ready to be mixed with water, comprising at least one powdery binder and at least one aggregate, as well as optionally at least one standard additive and/or adjuvant, and formed from particles, at least some of which, referred to as fine particles, are liable to produce an emission of dust, wherein the mortar composition also comprises a fluid additive that consists of at least one non-polar hydrocarbon organic substance chosen from amongst mineral oils, paraffin oils, paraffins, polyolefins or mixtures of these substances and that has a capacity for agglomeration of the said fine particles, and wherein the dry mortar composition comprises agglomerates of fine particles formed by the fluid additive. Also disclosed is a method of preparation of said mortar composition and its use.
Patent NZ-573439-A (NZ)
Title: Amino-piperidine derivatives as cetp inhibitors
Inventor: IMASE HIDETOMO
IPC: C07D401/12
Filed: 2007-07-18
Abstract: Disclosed herein are amino-piperidine compounds of formula (I), wherein the substituents are as defined within the specification, processes for its preparation, compositions comprising said compounds and uses thereof. Said compounds and compositions are useful in the in the treatment of a disorder or disease mediated by cholesteryl ester transfer protein (CETP), such as hyperlipidemia, arteriosclerosis, atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia, cardiovascular disorder, coronary heart disease, coronary artery disease, coronary vascular disease, angina, ischemia, heart ischemia, thrombosis, cardiac infarction stroke, peripheral vascular disease, reperfusion injury, angioplasty restenosis, hypertension, congestive heart failure, diabetes, diabetic vascular complications, obesity and endotoxemia.
Patent NZ-575683-A (NZ)
Title: Method for the univocal marking of materials, and ink for carring out the same
Inventor: SELVA CLAUDIO
IPC: B41M3/14
Filed: 2007-11-16
Abstract: Disclosed is a method for unique marking of material, including at least the following steps: a) producing an ink for marking the product to be rendered unique, made up of a vehicle suitable for the type of printing, machinery and printed product, which is mixed with microencapsulated microdrops of approximately 40 to 80 micrometers in diameter; b) printing on the product, using this particular ink, a sign of approximately one centimetre square, included in which is a progressive filing number; c) lighting up said sign, highlighting fully the randomness of distribution, the shape and size of the microencapsulated microdrops, thus creating an unrepeatable and differentiated background map for the sign entered; d) filtering first the reading datum consisting of said background map using a dark lens in order to neutralize and inhibit any possible reflectance of distortion and disturbance of the patterns, and then detecting said filtered reading datum, by means of an optical-to-digital camera connected to a software with a viewing device, which transmits the same datum possibly to a filing database for a future comparison and confirmation of authenticity on the product thus marked.
Patent NZ-582920-A (NZ)
Title: Multilayer film having active oxygen barrier layer and iron-based oxygen scavenging layer
Inventor: BECKWITH SCOTT
IPC: B32B27/00
Filed: 2008-07-15
Abstract: Disclosed is a multilayer active oxygen barrier film comprising: a) at least one active oxygen barrier layer comprising an oxygen scavenging composition that is a blend of: (A) a thermoplastic resin having carbon-carbon double bonds substantially in its main chain; (B) a transition metal salt; and (C) an oxygen barrier polymer, and b) an iron-based oxygen scavenging composition, wherein the film has an oxygen scavenging rate that is at least about 0.01 cc oxygen per day per gram of the oxygen scavenging composition blend. The film can be used to wrap or package food products.
Patent NZ-585543-A (NZ)
Title: Naphthalene-containing cyclic hydrocarbon compounds for the treatment of disturbances of calcium sensor receptor activity
Inventor: HAVEZ SOPHIE ELISABETH
IPC: C07C215/28
Filed: 2008-11-20
Abstract: Disclosed are cycloalkyl compounds of formula I wherein A is 1-naphthyl, salts and esters thereof, and methods for their preparation. Specific examples of compounds of formula I include: 3-((R)-1-naphthalen-1-yl-ethylamino)-cyclobutanecarboxylic acid, ((R)-1-Naphthalen-1-yl-ethyl)-{ 3-[3-(4-trifluoromethyl-phenyl)-[1,2,4]oxadiazol-5-yl]-cyclobutyl} -amine; hydrochloride, { [3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclobutanecarbonyl]-amino} -phenyl-acetic acid, 4-[3-((R)-1-naphthalen-1-yl-ethylamino)-cyclohexyl]-benzamidine, N-Benzyloxy-4-[3-((R)-1-naphthalen-1-yl-ethylamino)-cyclohexyl]-benzamide, and N-[3-(3-methoxyphenyl)cyclohexyl]-a-methyl-2-naphthalenemethanamine. Compounds of formula I are useful for treating physiological disorders or diseases associeated with disturbances of the calcium-sensing receptor (CaSR) activity, such as hyperparathyroidism.
Patent NZ-589438-A (NZ)
Title: A mount in two parts that trap a cymbol or similar between them and retained with a wire in a slot in the shaft it is mounted on
Inventor: MEADOWS LESLIE BRIAN
IPC: G10G5/00
Filed: 2010-11-22
Abstract: 589438 An apparatus for mounting a percussion instrument (10) onto a stand (11) is disclosed. The apparatus comprises a support portion (12) and a retaining portion (13). The support portion has a support member arranged for attachment to the stand and includes a shaft. The retaining portion has a gripping member with a pair of elements spaced apart and one or more spreader means arranged to urge the spaced apart elements away from each other. The support and retaining portions are used to mount the percussion instrument between them, the shaft engageable with the retaining portion. The elements of the gripping member are normally biased to a first position that is capable of retaining the shaft between the elements in a locked position in the said retaining portion, the elements movable to a second position in which the retaining portion can be received on or removed from the first position on the shaft, the elements movable from the first position to the second position by activation of the or each spreader means.
Patent NZ-591054-A (NZ)
Title: Desalinization apparatus and method by evaporating salt water into airstream in chamber along apparatus having pressurised inlets of water and air
Inventor: ROCK KELLY P
IPC: H05B44/00
Filed: 2009-08-11
Abstract: There is disclosed a desalinization apparatus, and methods related to desalinization. In an embodiment, a desalinization apparatus includes at least one port for receiving airflow therethrough, at least one port for receiving salt water therethrough, at least one output for providing outflow of pure water vapor, and at least one output for proving outflow of a mixture of water, salt and air; and a plurality of chambers for evaporating the salt water into the airflow, at least one of the chambers forming a plurality of ports arranged in a plurality of rows. In an embodiment, a method includes providing airflow to a desalinization apparatus; providing salt water to the desalinization apparatus; forming a vortex in the airflow to evaporate water vapor from the salt water; and providing the water vapor in the airflow to a condenser so as to obtain pure water.
Patent NZ-591724-A (NZ)
Title: A combined vaccine, comprising a primer composition comprising a meningococcal outer membrane vesicle preparation, and a booster composition comprising a meningococcal protein antigen preparation
Inventor: FEAVERS IAN
IPC: A61K39/095
Filed: 2009-09-04
Abstract: Disclosed is the use of a primer composition comprising a meningococcal outer membrane vesicle preparation, and a booster composition comprising a purified meningococcal protein antigen preparation, wherein the booster composition does not comprise outer membrane vesicles, for the preparation of a pharmaceutical combination for immunizing a subject against a disease caused by Neisseria meningitidis
Patent NZ-591900-A (NZ)
Title: Hinged sanding block
Inventor: ALLAN DONALD BRYCE
IPC: B24D11/06
Filed: 2011-03-24
Abstract: A hand held sanding block with a first and second body portion which are hingedly connected. At least one of the body portions includes a sandpaper retention part fitted to or formed on an inner surface for retaining a portion of a sheet of sandpaper. In use the outer surfaces of the first and second body portions define two or more backing surfaces to the sheet of retained sandpaper.
Patent NZ-592817-A (NZ)
Title: Laticed end cap for bee storage tube
Inventor: BERRY RUSSELL ARTHUR
IPC: B65D81/18
Filed: 2008-12-08
Abstract: An end cap (1) for plugging or capping an end of a hollow elongate member for bee storage and/or transportation. The cap has a tubular latticed or perforate wall (7) extending between a first end at which it extends into a feature or features (3) to plug into an elongate member, and a second end which is enclosed.
Patent NZ-594217-A (NZ)
Title: Novel saponin compounds, methods of preparation thereof, use thereof and pharmaceutical compositions
Inventor: WOJTKIELEWICZ AGNIESZKA
IPC: A61K31/58
Filed: 2010-02-08
Abstract: Disclosed are saponin compounds of Formula II, and methods of their preparation. Specific examples of compounds of Formula II include (20S)-21-benzyloxy-20-methylpregn-5-ene-3[beta],16[beta]17[alpha]-triol 16-O-{ 2-O-(4-methoxybenzoyl)-[beta]-D-xylopyranosyl-(13)-2'-O-acetyl-[alpha]-L-arabinopyranoside, and (20R)-21-O-pentanoyl-20-methylpregn-5-ene-3[beta],16[beta],17[alpha],21-tetraol 16-O-{ 2-O-(4-methoxybenzoyl)-[beta]-D-xylopyranosyl-(13)-2'-O-acetyl-[alpha]-L-arabinopyranoside} . The saponin compounds inhibit cell proliferation and induce cell apoptosis. The compounds are useful for treating proliferative disorders such as cancer, restenosis, rheumatoid arthritis, lupus, type I diabetes, multiple sclerosis, Alzheimer´s disease, growth of parasites, graft rejection, graft versus host disease, polycystic kidney disease, and gout.
Patent NZ-594848-A (NZ)
Title: Use of adipose tissue-derived stromal stem cells in treating fistula
Inventor: GARCIA CASTRO ROSA ANA
IPC: A61K35/12
Filed: 2006-05-16
Abstract: Provided is the use of a composition comprising allogeneic adipose tissue-derived stromal stem cells in the manufacture of a pharmaceutical composition for treating fistula in a subject. The cells may be selected by using markers indicating the expression of CD9, CD10, CD13. CD29, CD44, CD49A. CD51, CD54, CD55, CD58, CD59 CD90 and CD105 in the cells.
Patent NZ-595335-A (NZ)
Title: Pharmaceutical comprising (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide with enhanced bioavailability and solubility
Inventor: CHANDRAN SACHIN
IPC: A61K31/4245
Filed: 2010-04-13
Abstract: Disclosed is an alpha-(N-sufonamido)acetamide derivative as part of a pharmaceutical composition comprising: (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide, Polyethylene glycol (PEG), Vitamin E polyethylene glycol succinate (TPGS), A crystallization inhibitor member selected from the group consisting of polyvinylpryrrolidone (PVP) and copovidone (PVP-Polyvinyl acetate), and Citric acid. The pharmaceutical composition is a Beta amyloid peptide production inhibitor and is useful for treating Alzheimer's disease, cerebral amyloid angiopathy, mild cognitive impairment and/or Down syndrome, as well as the treatment of head trauma, traumatic brain injury, and/or dementia pugilistica.
Patent NZ-600145-A (NZ)
Title: Use of methylsulfonylmethane (msm) to modulate microbial activity
Inventor: VARELMAN JEFFREY
IPC: C12H6/00
Filed: 2010-10-29
Abstract: 600145 Disclosed herein are methods of use of methylsulfonylmethane (MSM) to modulate microbial activity, such as to enhance or inhibit the activity of microorganisms. In one example, MSM (such as about 0.5% to 5% MSM) is used to enhance fermentation efficiency, such as to enhance fermentation efficiency associated with the production of beer, cider, wine, a biofuel, dairy product or any combination thereof. Also disclosed are in vitro methods for enhancing the growth of one or more probiotic microorganisms and methods of enhancing growth of a microorganism in a diagnostic test sample. Methods of inhibiting microbial activity are also disclosed. In one particular example, a method of inhibiting microbial activity includes selecting a medium that is susceptible to H1N1 influenza contamination; and contacting the medium with MSM at a concentration of about 10% to about 16% of weight by volume, thereby inhibiting H1N1 influenza microbial activity.
Patent NZ-600408-A (NZ)
Title: Segregated in-situ forced oxidation wet flue gas desulfurization for oxygen-fired fossil fuel combustion
Inventor: ROGERS KEVIN J
IPC: B01D53/50
Filed: 2010-10-11
Abstract: 600408 Provided are an in-situ forced oxidation wet flue gas desulfurization apparatus, method and arrangement for utilization with oxy-fuel combustion power plants. The apparatus is a tower-like structure having a flue gas scrubbing zone and a reaction zone located subjacent to the gas scrubbing zone. A sulfur oxide absorbing liquid slurry is supplied to the gas scrubbing zone to react with and scrub the sulfur oxides from the flue gas. The partially reacted liquid slurry reagent and the scrubbed products drain into the reaction zone, rising to a set level. Oxidation air is introduced into the liquid slurry in the reaction zone to force the in-situ oxidation of sulfur compounds collected in the reaction zone. A wall separates and communicates the gas scrubbing zone and the reaction zone, the wall prevents the oxidation air from entering the gas scrubbing zone and extends into the liquid slurry below a nominal depth required to establish and maintain a liquid slurry seal thereby substantially precluding the leakage of flue gas into the reaction zone while allowing the partially reacted liquid slurry reagent and scrubbed products to drain into the reaction zone.
Patent NZ-612686-A (NZ)
Title: Sublingual films
Inventor: BRYSON NATHAN JOHN
IPC: A61K47/38
Filed: 2011-12-16
Abstract: Provided are sublingual film pharmaceutical compositions comprising dopamine agonists. Preferred dopamine agonists are apomorphine or ropinerol (ropinirole). In one embodiment the composition is in a unit dosage form formulated for sublingual administration, wherein said unit dosage form is a film comprising: (A) a first layer comprising: (i) from 10 to 75% (w/w) apomorphine hydrochloride; (ii) from 0.5 to 10% (w/w) a low molecular weight polymer having a weight average molecular weight of from 5 KDa to 50 KDa selected from hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, and methyl cellulose; and (iii) from 4 to 35% (w/w) a high molecular weight polymer having a weight average molecular 15 weight of greater than 60 KDa selected from hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, and methyl cellulose; and (B) a second layer comprising: (iv) from 6 to 65% (w/w) a pH neutralizing agent that is an organic base having a pKa of 5 ± 2, and (v) from 15 to 50% (w/w) of a high molecular weight polymer having a weight average molecular weight of greater than 60 KDa selected from hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, and methyl cellulose, wherein said first layer comprises from 2 to 60 mg of apomorphine hydrochloride. In another embodiment the composition is in unit dosage form formulated for sublingual administration, wherein said unit dosage form is a film comprising a first layer and a second layer, wherein the first layer comprises from 2 to 60 mg of apomorphine hydrochloride and wherein the second layer comprises a pH neutralizing agent that is an organic base having a pKa of 5 ± 2, wherein said organic base is selected from the group consisting of pyridoxine, citrate, and histidine. The formulations are useful in the treatment of Parkinson’s disease, tremors, restless leg syndrome, sexual dysfunction and depressive disorders.
Patent NZ-615847-A (NZ)
Title: Recombinant production of peptides
Inventor: SCHWALB CARSTEN
IPC: C12N15/74
Filed: 2010-06-02
Abstract: Disclosed is a precursor protein comprising a cleavable sequence of desired peptide (Pep) elements and auxiliary peptide (Aux’) elements of the general formula (Pep-Aux’)x or (Aux’-Pep)x where x >1, wherein: the Aux’ elements are identical or different and comprise an amphiphilic alphahelix-forming peptide, said amphiphilic peptide comprising a sequence segment of at least seven peptidically linked amino acids capable of forming an amphiphilic alpha-helix, wherein the amino acid residues of said helix in its vertical projection are separated into a hydrophobic half and a hydrophilic half of the helix, the hydrophobic half of the helix having at least 3 adjacent, in the vertical projection, identical or different hydrophobic amino acid residues, and the hydrophilic half of the helix having at least 3 adjacent, in the vertical projection, identical or different hydrophilic amino acid residues; the Pep elements are identical or different and comprise the amino acid sequence of identical or different peptide molecules having a sequence length of 5 to 70 amino acid residues; the Pep elements are flanked by cleavage sequences which enable the Pep elements to be specifically cleaved out of the precursor protein; and Pep is a cationic antimicrobial peptide and Aux’ is an anionic peptide forming an amphiphilic alpha helix. Further disclosed is the use of an amphiphilic peptide as protective peptide for recombinantly producing an antimicrobial desired peptide different therefrom; wherein said amphiphilic peptide comprises a sequence section of at least seven peptidically linked amino acids capable of forming an amphiphilic alpha-helix, wherein the amino acid residues of said helix in its vertical projection are separated into a hydrophobic half and a hydrophilic half of the helix, the hydrophobic half of the helix having at least 3 adjacent, in the vertical projection, identical or different hydrophobic amino acid residues, and the hydrophilic half of the helix having at least 3 adjacent, in the vertical projection, identical or different hydrophilic amino acid residues.
Patent NZ-623840-A (NZ)
Title: Anti-cd134 (ox40) antibodies and uses thereof
Inventor: SIMONS PETRUS JOHANNES
IPC: C07K16/28
Filed: 2012-09-13
Abstract: A binding molecule that binds to human CD134 (OX40), wherein the binding molecule is an antibody or antigen binding fragment comprising: (a) a heavy chain CDR1 comprising the amino acid sequence of GYTFTSYVMH; (b) a heavy chain CDR2 comprising the amino acid sequence of YINPYNDGTKYNEKFKG; (c) a heavy chain CDR3 comprising the amino acid sequence of YYGSSLSMDY; and a light chain variable region comprising: (a) a light chain CDRl comprising the amino acid sequence of RASQDISNYLN; (b) a light chain CDR2 comprising the amino acid sequence of YTSRLHS; (c) a light chain CDR3 comprising the amino acid sequence of QQGNTLPWT.
Patent NZ-630110-A (NZ)
Title: A cup with integral closure flaps restricting spillage
Inventor: LU WEI
IPC: B65D3/30
Filed: 2013-05-27
Abstract: Disclosed is a drinking vessel with integrated flaps to reduce spillage. The container (1) comprisies a wall (2) having a closed base (4) at one end and a generally circular or oval rim (5) of at an opposite end, the rim defining a top opening (6) of the container. The container (1) further comprises an arrangement of flaps (70, 80) whereby the counteracting forces between a rim of a first flap (70) and the inner face of a second flap (80) are sufficient to push the respective rim and the inner face together into a tight contact. A closure arrangement (300a, 300b) is provided to restrict flap openings (100a, 100b) formed at or below the rim (5) of the container between the flaps (70, 80) to prevent splashing and reduce the rate of spillage if the container is knocked over. The cup thus has improved spill-resistant properties for the container (1), whilst, if required for drinking or pouring, permitting the container to allow the passage of a liquid when tilted for drinking and pouring.